ASH Annual Meeting   |  December 3, 2019   Proof-of-Concept Study of CAR-NK Cell Therapy with Engineered Persistence Shows Potential Robert A. Brodsky, MD discussed the study of a first-of-kind multi-antigen targeted off-the-shelf chimeric antigen receptor- natural killer cell therapy with engineered persistence that will be presented at the ASH Annual Meeting & Exposition. Read more advertisement   CAR T-Cell Therapy Studies to Look for at the ASH Annual Meeting Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment. Read more